Clinical Trial Update: Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of LY2940094 in adults with major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• LY2940094

Snippet

Sponsor: BlackThorn Therapeutics, Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED